Welcome to our dedicated page for Traws Pharma news (Ticker: TRAW), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company whose news flow centers on the development of investigational oral antivirals for major respiratory viral threats. Company announcements frequently highlight progress in its COVID-19 and influenza programs, including clinical trial milestones, interim data readouts, regulatory interactions and partnering activities.
A key focus of Traws’ news coverage is ratutrelvir, an investigational oral Mpro (3CL protease) inhibitor designed to treat SARS-CoV-2/COVID-19 without ritonavir. Recent press releases describe Phase 2 studies that compare ratutrelvir with PAXLOVID in patients with mild-to-moderate COVID-19 and evaluate its use in PAXLOVID-ineligible patients who face drug–drug interaction concerns with ritonavir-boosted regimens. Interim analyses reported by the company discuss patient-reported symptom outcomes, safety, tolerability and the presence or absence of viral or symptom rebound, as well as potential implications for Long COVID.
News items also cover tivoxavir marboxil (TXM), an investigational single-dose CAP-dependent endonuclease inhibitor for bird flu and seasonal influenza. Traws’ updates describe Phase 1 findings, preclinical results in multiple animal models using H5N1 virus, and interactions with agencies such as BARDA regarding potential inclusion of TXM in antiviral stockpiling initiatives for pandemic preparedness.
Investors following TRAW news can expect regular disclosures on quarterly financial results, business highlights, intellectual property and asset acquisitions, board and management changes, and corporate governance matters, as reflected in the company’s earnings releases and SEC filings. In addition, third-party announcements from collaborators, such as organizations providing chemistry, manufacturing and controls or AI-enabled predictive pharmacology support for ratutrelvir, may reference Traws’ clinical progress.
This news page aggregates these developments so readers can monitor how Traws’ clinical data, regulatory milestones and strategic decisions evolve over time. For those tracking antiviral pipelines for COVID-19, Long COVID, bird flu and seasonal influenza, the TRAW news feed offers a centralized view of the company’s publicly reported activities.
Traws Pharma announced its Q1 2024 financial results and provided a business update, highlighting significant developments. The company completed the acquisition of Trawsfynydd and raised $14 million in private placement financing.
Key pipeline advancements include the initiation of first-in-human dosing for their COVID-19 product candidate and completion of the last dose escalation cohort for their CDK4+ inhibitor, narazaciclib. They plan to advance their influenza treatment and ritonavir-free COVID-19 protease inhibitor into expanded Phase 1 and Phase 2 studies in H2 2024.
First quarter financials show cash and equivalents at $16.4 million, a slight decrease from $20.8 million at the end of 2023. Revenue remained consistent at $56,000. G&A expenses rose to $3.4 million due to acquisition-related costs, while R&D expenses decreased to $1.9 million. The net loss narrowed to $5.0 million from $5.8 million in Q1 2023.
Traws Pharma completed dosing in the first cohort of the Phase 1 study for its COVID-19 therapy, travatrelvir. The oral protease inhibitor showed preclinical activity against multiple SARS-CoV-2 variants, doesn't need ritonavir co-administration, and is in line for Phase 2 starting later in 2024.